Feasibility study for chemobrain

Feasibility study for chemobrain - Feasibility study for chemobrain

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030120

Enrollment

Registered

2021-03-31

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients

Interventions

administration of neuroprotective agent coadministration with chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: cancer patients receiving chemotherapy

Exclusion criteria

Exclusion criteria: severe cognitive decline

Design outcomes

Primary

Measure	Time frame
biomarker for axonal damage	—

Secondary

Measure	Time frame
safety	—

Countries

Japan

Contacts

Public ContactMasahiko Sumitani

The University of Tokyo Hospital

sumitanim-ane@h.u-tokyo.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026